JPMorgan Chase & Co. Has $614,000 Stock Position in Enhabit, Inc. (NYSE:EHAB)

JPMorgan Chase & Co. cut its stake in Enhabit, Inc. (NYSE:EHAB - Free Report) by 74.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,574 shares of the company's stock after selling 226,671 shares during the period. JPMorgan Chase & Co. owned approximately 0.16% of Enhabit worth $614,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Enhabit during the 4th quarter valued at $45,000. Corient Private Wealth LLC purchased a new stake in Enhabit during the fourth quarter valued at about $79,000. Stoneridge Investment Partners LLC grew its position in Enhabit by 22.6% during the fourth quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company's stock valued at $98,000 after acquiring an additional 2,308 shares during the period. Intech Investment Management LLC raised its holdings in shares of Enhabit by 27.6% in the 4th quarter. Intech Investment Management LLC now owns 15,481 shares of the company's stock worth $121,000 after purchasing an additional 3,353 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Enhabit in the 4th quarter valued at about $124,000.

Enhabit Price Performance

EHAB stock traded up $0.04 during trading hours on Monday, hitting $8.09. 17,012 shares of the stock traded hands, compared to its average volume of 311,168. Enhabit, Inc. has a one year low of $6.85 and a one year high of $10.70. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The company has a market cap of $408.13 million, a P/E ratio of -3.49 and a beta of 1.60. The stock has a 50-day simple moving average of $8.28 and a 200 day simple moving average of $8.03.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reiterated a "buy" rating on shares of Enhabit in a report on Thursday, March 6th.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.